Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker BCRX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glom… NCT05162066 · Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy BCX9930 | BCRX BioCryst Pharmaceuticals | Phase 2 | Terminated | 2 | Sep 23, 2022 | Registry ↗ |
| Nov 10, 2026 | BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequ… NCT05116774 · Paroxysmal Nocturnal Hemoglobinuria (PNH) Eculizumab, Ravulizumab | BCRX BioCryst Pharmaceuticals | Phase 2 | Terminated | 12 | Sep 14, 2023 | Registry ↗ |
| Nov 6, 2026 | A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 NCT06539507 · Netherton Syndrome BCX17725, Placebo | BCRX BioCryst Pharmaceuticals | Phase 1 | Active, not recruiting was recruiting | 76 | Dec 2026 | Registry ↗ |
| Oct 29, 2026 | BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receivin… NCT05116787 · Paroxysmal Nocturnal Hemoglobinuria (PNH) Placebo, BCX9930 monotherapy | BCRX BioCryst Pharmaceuticals | Phase 2 | Terminated | 12 | Sep 18, 2023 | Registry ↗ |
| Jun 10, 2026 | A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated… NCT01224795 · Influenza Peramivir, Placebo Comparator | BCRX BioCryst Pharmaceuticals | Phase 3 | Withdrawn | 0 | Nov 2010 | Registry ↗ |
| Jun 1, 2026 | Intramuscular Peramivir for the Treatment of Uncomplicated Influenza NCT00486980 · Influenza Peramivir 150mg, Peramivir 300mg | BCRX BioCryst Pharmaceuticals | Phase 3 | Withdrawn | 0 | — | Registry ↗ |
| May 11, 2026 | A Study of Avoralstat In Participants With Diabetic Macular Edema NCT07228559 · Diabetic Macular Edema (DME) avoralstat | BCRX BioCryst Pharmaceuticals | Phase 1 | Terminated | 3 | Apr 17, 2026 | Registry ↗ |
| Feb 25, 2026 | Berotralstat Treatment in Children With Hereditary Angioedema NCT05453968 · Hereditary Angioedema, Pediatric Berotralstat | BCRX BioCryst Pharmaceuticals | Phase 3 | Active, not recruiting | 29 | Sep 11, 2024 | Registry ↗ |
| Dec 23, 2025 | Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies NCT04933721 · Hereditary Angioedema, HAE berotralstat | BCRX BioCryst Pharmaceuticals | Phase 3 | Enrolling by invitation | 139 | Aug 2031 | Registry ↗ |
| Nov 17, 2025 | 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks NCT02303626 · Hereditary Angioedema, HAE BCX4161, Placebo | BCRX BioCryst Pharmaceuticals | Phase 2/3 | Completed | 110 | Jan 2016 | Registry ↗ |
| Oct 24, 2025 | Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria NCT05741346 · Paroxysmal Nocturnal Hemoglobinuria BCX9930 | BCRX BioCryst Pharmaceuticals | Phase 2 | Terminated | 28 | Jan 31, 2025 | Registry ↗ |
| Apr 13, 2025 | A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) NCT04702568 · Paroxysmal Nocturnal Hemoglobinuria, PNH BCX9930, Eculizumab | BCRX BioCryst Pharmaceuticals | Phase 2 | Terminated | 19 | Oct 4, 2023 | Registry ↗ |
| Jan 8, 2025 | Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) NCT06100900 · Paroxysmal Nocturnal Hemoglobinuria BCX10013 | BCRX BioCryst Pharmaceuticals | Phase 1 | Completed | 8 | Dec 11, 2024 | Registry ↗ |
| Jul 19, 2024 | Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE… NCT03873116 · Hereditary Angioedema, HAE BCX7353 capsules, BCX7353 capsules | BCRX BioCryst Pharmaceuticals | Phase 3 | Completed | 19 | Jul 8, 2021 | Registry ↗ |
| Jun 26, 2023 | Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE NCT03485911 · Hereditary Angioedema, HAE BCX7353 capsules, Placebo oral capsule | BCRX BioCryst Pharmaceuticals | Phase 3 | Completed | 121 | Apr 10, 2019 | Registry ↗ |
| Jun 18, 2023 | A Long Term Safety Study of BCX7353 in Hereditary Angioedema NCT03472040 · Hereditary Angioedema, HAE BCX7353 | BCRX BioCryst Pharmaceuticals | Phase 2/3 | Completed | 387 | Apr 27, 2022 | Registry ↗ |
| Feb 17, 2022 | First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH NCT04330534 · Paroxysmal Nocturnal Hemoglobinuria BCX9930, Placebo | BCRX BioCryst Pharmaceuticals | Phase 1/2 | Completed | 168 | Nov 11, 2020 | Registry ↗ |
| Jul 23, 2021 | A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430 NCT03800173 · Marburg Virus Disease galidesivir, placebo | BCRX BioCryst Pharmaceuticals | Phase 1 | Completed | 32 | Apr 30, 2019 | Registry ↗ |
| May 27, 2021 | A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fev… NCT03891420 · COVID-19, Yellow Fever Galidesivir, Placebo | BCRX BioCryst Pharmaceuticals | Phase 1 | Terminated | 24 | Jan 31, 2021 | Registry ↗ |
| Apr 1, 2021 | Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema NCT03240133 · Hereditary Angioedema (HAE) BCX7353, Placebo | BCRX BioCryst Pharmaceuticals | Phase 2 | Completed | 58 | Jan 29, 2019 | Registry ↗ |
| Mar 23, 2021 | Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema NCT02870972 · Hereditary Angioedema (HAE) BCX7353, Placebo | BCRX BioCryst Pharmaceuticals | Phase 2 | Completed | 75 | Aug 2017 | Registry ↗ |
| Mar 23, 2021 | Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated… NCT02635724 · Influenza Peramivir | BCRX BioCryst Pharmaceuticals | Phase 3 | Completed | 74 | Apr 2018 | Registry ↗ |
| Mar 23, 2021 | Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncompli… NCT02369159 · Influenza Peramivir, Oseltamivir | BCRX BioCryst Pharmaceuticals | Phase 3 | Completed | 137 | Oct 28, 2019 | Registry ↗ |
| Mar 17, 2021 | Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza NCT00610935 · Influenza Peramivir, Placebo | BCRX BioCryst Pharmaceuticals | Phase 3 | Terminated | 82 | Feb 2008 | Registry ↗ |
| Dec 11, 2020 | Oral Berotralstat Expanded Access Program NCT04428632 · Hereditary Angioedema, HAE Berotralstat | BCRX BioCryst Pharmaceuticals | — | Approved for marketing | — | — | Registry ↗ |
| Jan 27, 2020 | A Relative Bioavailability Study of Two Formulations of BCX7353 NCT03202784 · Hereditary Angioedema BCX7353 | BCRX BioCryst Pharmaceuticals | Phase 1 | Completed | 24 | Aug 1, 2017 | Registry ↗ |
| Oct 26, 2017 | A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions NCT03136237 · Hereditary Angioedema BCX7353, Digoxin | BCRX BioCryst Pharmaceuticals | Phase 1 | Completed | 54 | Aug 15, 2017 | Registry ↗ |
| Jan 31, 2017 | An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzy… NCT02819102 · Hereditary Angioedema BCX7353 and probes | BCRX BioCryst Pharmaceuticals | Phase 1 | Completed | 20 | Jun 2016 | Registry ↗ |
| Jul 7, 2016 | A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430 NCT02319772 · Filovirus Infections, Ebola Virus Infection BCX4430, Placebo | BCRX BioCryst Pharmaceuticals | Phase 1 | Completed | 94 | Mar 2016 | Registry ↗ |
| Feb 17, 2016 | Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema NCT02670720 · Hereditary Angioedema, HAE avoralstat | BCRX BioCryst Pharmaceuticals | Phase 3 | Terminated | 6 | Feb 2016 | Registry ↗ |
| Jan 13, 2016 | First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of… NCT02448264 · Hereditary Angioedema BCX7353, Placebo to match BCX7353 | BCRX BioCryst Pharmaceuticals | Phase 1 | Completed | 122 | Nov 2015 | Registry ↗ |
| Feb 16, 2015 | A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety… NCT00705406 · Acute, Uncomplicated Human Influenza Peramivir, Placebo | BCRX BioCryst Pharmaceuticals | Phase 2 | Completed | 405 | Apr 2009 | Registry ↗ |
| Feb 12, 2015 | A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compare… NCT00958776 · Cough, Sore Throat Peramivir+SOC, Placebo+SOC | BCRX BioCryst Pharmaceuticals | Phase 3 | Terminated | 405 | Nov 2012 | Registry ↗ |
| Feb 12, 2015 | Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza NCT00957996 · Seasonal Influenza, Cough Peramivir, Peramivir | BCRX BioCryst Pharmaceuticals | Phase 3 | Completed | 234 | Oct 2010 | Registry ↗ |
| Feb 12, 2015 | Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-thr… NCT00453999 · Influenza Peramivir 200 mg, Peramivir 400 mg | BCRX BioCryst Pharmaceuticals | Phase 2 | Completed | 137 | Sep 2008 | Registry ↗ |
| Feb 12, 2015 | Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza. NCT00419263 · Influenza Peramivir 150 mg, Peramivir 300 mg | BCRX BioCryst Pharmaceuticals | Phase 2 | Completed | 344 | Sep 2007 | Registry ↗ |
36 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:47 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances